N
Neal L. Benowitz
Researcher at University of California, San Francisco
Publications - 825
Citations - 66786
Neal L. Benowitz is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Nicotine & Cotinine. The author has an hindex of 126, co-authored 792 publications receiving 60658 citations. Previous affiliations of Neal L. Benowitz include Shaare Zedek Medical Center & University College London.
Papers
More filters
Journal ArticleDOI
Mitochondrial DNA Content: Its Genetic Heritability and Association With Renal Cell Carcinoma
Jinliang Xing,Meng Chen,Christopher G. Wood,Jie Lin,Margaret R. Spitz,Jianzhong Ma,Christopher I. Amos,Peter G. Shields,Neal L. Benowitz,Jian Gu,Mariza de Andrade,Gary E. Swan,Xifeng Wu +12 more
TL;DR: In this article, the mtDNA content appears to have high heritability and a statistically significant dose-response relationship was detected between lower mtDNA contents and an increased risk of renal cell carcinoma.
Journal ArticleDOI
The pharmacogenetics research network: from SNP discovery to clinical drug response.
Kathleen M. Giacomini,Claire M. Brett,Russ B. Altman,Neal L. Benowitz,M E Dolan,David A. Flockhart,Julie A. Johnson,Daniel F. Hayes,Teri E. Klein,Ronald M. Krauss,Deanna L. Kroetz,Howard L. McLeod,Anne T. Nguyen,Mark J. Ratain,M. V. Relling,Victor I. Reus,Dan M. Roden,Catherine Schaefer,Alan R. Shuldiner,Todd C. Skaar,Kelan G. Tantisira,Rachel F. Tyndale,Liewei Wang,Richard M. Weinshilboum,Scott T. Weiss,Issam Zineh +25 more
TL;DR: This report highlights selected achievements and scientific approaches as well as hypotheses about future directions of each of the groups within the PGRN, including informatics, cardiovascular, pulmonary, addiction, cancer, transport, and metabolism.
Journal ArticleDOI
Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers
TL;DR: The disposition pharmacokinetics of nicotine was similar for the low and high doses in the smokers, indicating that metabolism is dose‐independent, and argues against “metabolic tolerance” as a mechanism for the dose escalation observed in smokers after initiation of smoking.
Journal ArticleDOI
Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study.
Maciej L. Goniewicz,Maciej L. Goniewicz,Michal Gawron,Danielle M Smith,Margaret Peng,Peyton Jacob,Neal L. Benowitz +6 more
TL;DR: This is the first study that demonstrates that substituting tobacco cigarettes with an e-cigarette may reduce user exposure to numerous toxicants and carcinogens otherwise present in tobacco cigarettes.
Journal ArticleDOI
Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial
Caryn Lerman,Robert A. Schnoll,Larry W. Hawk,Paul M. Cinciripini,Tony P. George,E. Paul Wileyto,Gary E. Swan,Neal L. Benowitz,Daniel F. Heitjan,Rachel F. Tyndale,Rachel F. Tyndale +10 more
TL;DR: In this paper, a NMR-stratified multicentre, randomised, placebo-controlled clinical trial from Nov 16, 2010, to Sept 12, 2014, at four sites was conducted to test whether a genetically informed biomarker of nicotine clearance, the nicotine metabolite ratio, predicts response to nicotine patch or varenicline for smoking cessation.